<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">62592</article-id><article-id pub-id-type="doi">10.7554/eLife.62592</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-205016"><name><surname>Gillis</surname><given-names>Joanna L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205017"><name><surname>Hinneh</surname><given-names>Josephine A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205018"><name><surname>Ryan</surname><given-names>Natalie K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167713"><name><surname>Irani</surname><given-names>Swati</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167716"><name><surname>Moldovan</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205019"><name><surname>Quek</surname><given-names>Lake-Ee</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167715"><name><surname>Shrestha</surname><given-names>Raj K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247080"><name><surname>Hanson</surname><given-names>Adrienne R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247079"><name><surname>Xie</surname><given-names>Jianling</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167721"><name><surname>Hoy</surname><given-names>Andrew J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3922-1137</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195568"><name><surname>Holst</surname><given-names>Jeff</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0377-9318</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167714"><name><surname>Centenera</surname><given-names>Margaret M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205020"><name><surname>Mills</surname><given-names>Ian G</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167720"><name><surname>Lynn</surname><given-names>David J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-205021"><name><surname>Selth</surname><given-names>Luke A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-146475"><name><surname>Butler</surname><given-names>Lisa M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2698-3220</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Medicine</institution>, <institution>University of Adelaide</institution>, <addr-line><named-content content-type="city">Adelaide</named-content></addr-line>, <country>Australia</country></aff><aff id="aff2"><institution content-type="dept">Precision Medicine</institution>, <institution>South Australian Health and Medical Research Institute</institution>, <addr-line><named-content content-type="city">Adelaide</named-content></addr-line>, <country>Australia</country></aff><aff id="aff3"><institution content-type="dept">Charles Perkins Centre</institution>, <institution>University of Sydney</institution>, <addr-line><named-content content-type="city">Sydney</named-content></addr-line>, <country>Australia</country></aff><aff id="aff4"><institution>Flinders University</institution>, <addr-line><named-content content-type="city">Bedford Park</named-content></addr-line>, <country>Australia</country></aff><aff id="aff5"><institution content-type="dept">School of Medical Sciences</institution>, <institution>University of New South Wales</institution>, <addr-line><named-content content-type="city">Sydney</named-content></addr-line>, <country>Australia</country></aff><aff id="aff6"><institution content-type="dept">Centre for Cancer Research and Cell Biology</institution>, <institution>Queen's University Belfast</institution>, <addr-line><named-content content-type="city">Belfast</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-10241"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role>Reviewing editor</role><aff><institution>Jewish General Hospital</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>luke.selth@flinders.edu.au</email> (LS);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>lisa.butler@adelaide.edu.au</email> (LB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>08</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e62592</elocation-id><history><date date-type="received"><day>29</day><month>08</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Gillis et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Gillis et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-62592-v1.pdf"/><abstract><p>Alterations to the androgen receptor (AR) signalling axis and cellular metabolism are hallmarks of prostate cancer. This study provides insight into both hallmarks by uncovering a novel link between AR and the pentose phosphate pathway (PPP). Specifically, we identify 6-phosphogluoconate dehydrogenase (<italic>6PGD</italic>) as an androgen-regulated gene that is upregulated in prostate cancer. AR increased the expression of <italic>6PGD </italic>indirectly via activation of sterol regulatory element binding protein 1 (SREBP1). Accordingly, loss of 6PGD, AR or SREBP1 resulted in suppression of PPP activity, as revealed by 1,2-<sup>13</sup>C<sub>2</sub> glucose metabolic flux analysis. Knockdown of 6PGD also impaired growth and elicited death of prostate cancer cells, at least in part due to increased oxidative stress. We investigated the therapeutic potential of targeting 6PGD using two specific inhibitors, physcion and S3, and observed substantial anti-cancer activity in multiple models of prostate cancer, including aggressive, therapy-resistant models of castration-resistant disease as well as prospectively-collected patient-derived tumour explants. Targeting of 6PGD was associated with two important tumour-suppressive mechanisms: first, increased activity of the AMP-activated protein kinase (AMPK), which repressed anabolic growth-promoting pathways regulated by ACC1 and mTOR; and second, enhanced AR ubiquitylation, associated with a reduction in AR protein levels and activity. Supporting the biological relevance of positive feedback between AR and PGD, pharmacological co-targeting of both factors was more effective in suppressing the growth of prostate cancer cells than single agent therapies. Collectively, this work provides new insight into the dysregulated metabolism of prostate cancer and provides impetus for further investigation of co-targeting AR and the PPP as a novel therapeutic strategy.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001111</institution-id><institution>Cancer Australia</institution></institution-wrap></funding-source><award-id>1138766</award-id><principal-award-recipient><name><surname>Centenera</surname><given-names>Margaret M</given-names></name><name><surname>Mills</surname><given-names>Ian G</given-names></name><name><surname>Lynn</surname><given-names>David J</given-names></name><name><surname>Butler</surname><given-names>Lisa M</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008719</institution-id><institution>Movember Foundation</institution></institution-wrap></funding-source><award-id>MRTA3</award-id><principal-award-recipient><name><surname>Hoy</surname><given-names>Andrew J</given-names></name><name><surname>Centenera</surname><given-names>Margaret M</given-names></name><name><surname>Selth</surname><given-names>Luke A</given-names></name><name><surname>Butler</surname><given-names>Lisa M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000927</institution-id><institution>Prostate Cancer Foundation of Australia</institution></institution-wrap></funding-source><award-id>MRTA3</award-id><principal-award-recipient><name><surname>Hoy</surname><given-names>Andrew J</given-names></name><name><surname>Centenera</surname><given-names>Margaret M</given-names></name><name><surname>Selth</surname><given-names>Luke A</given-names></name><name><surname>Butler</surname><given-names>Lisa M</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000950</institution-id><institution>Cancer Council South Australia</institution></institution-wrap></funding-source><award-id>Principal Cancer Research Fellowships</award-id><principal-award-recipient><name><surname>Selth</surname><given-names>Luke A</given-names></name><name><surname>Butler</surname><given-names>Lisa M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Prostate cancer tissue was obtained with informed written consent through the Australian Prostate Cancer BioResource from men undergoing radical prostatectomy at St Andrew's Hospital (Adelaide, Australia). Ethical approval for the use of human prostate tumours was obtained from the Ethics Committees of the University of Adelaide (Adelaide, Australia) and St Andrew's Hospital (Adelaide, Australia). All experiments were performed in accordance with the guidelines of the National Health and Medical Research Council (Australia).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 1.Sequencing data have been deposited in GEO under accession code GSE152254</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Gillis JL</collab><collab>Hinneh JA</collab><collab>Ryan NK</collab><collab>Irani S</collab><collab>Moldovan M</collab><collab>Quek LE</collab><collab>Hoy AJ</collab><collab>Holst J</collab><collab>Centenera MM</collab><collab>Mills IG</collab><collab>Lynn DJ</collab><collab>Selth LA</collab><collab>Butler LM</collab></person-group><year iso-8601-date="2020">2020</year><source>A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth</source><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152254">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152254</ext-link><comment>NCBI Gene Expression Omnibus, GSE152254</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>TCGA</collab></person-group><year iso-8601-date="2015">2015</year><source>The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD)</source><ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/projects/TCGA-PRAD">https://portal.gdc.cancer.gov/projects/TCGA-PRAD</ext-link><comment>National Cancer Institute, TCGA-PRAD</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Rajan P</collab><collab>Sudbery IM</collab><collab>Villasevil ME</collab><collab>Mui E</collab><collab>Fleming J</collab><collab>Davis M</collab><collab>Ahmad I</collab><collab>Edwards J</collab><collab>Sansom OJ</collab><collab>Sims D</collab><collab>Ponting CP</collab><collab>Heger A</collab><collab>McMenemin RM</collab><collab>Pedley ID</collab><collab>Leung HY.</collab></person-group><year iso-8601-date="2013">2013</year><source>The Wnt/Î²-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth</source><ext-link ext-link-type="uri" xlink:href="https://www-ncbi-nlm-nih-gov /geo/query/acc.cgi?acc=GSE48403">https://www-ncbi-nlm-nih-gov /geo/query/acc.cgi?acc=GSE48403</ext-link><comment>NCBI The Gene Expression Omnibus, GSE48403</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Pomerantz MM</collab><collab>Li F</collab><collab>Takeda D</collab><collab>Chonkar A</collab><collab>Chabot M</collab><collab>Li Q</collab><collab>Cejas P</collab><collab>Vazquez F</collab><collab>Shivdasani RA</collab><collab>Seo J</collab><collab>Bowden M</collab><collab>Lis R</collab><collab>Hahn WC</collab><collab>Kantoff PW</collab><collab>Brown M</collab><collab>Loda M</collab><collab>Long HW</collab><collab>Freedman ML.</collab></person-group><year iso-8601-date="2015">2015</year><source>Androgen receptor programming in human tissue implicates HOXB13 in prostate pathogenesis [ChIP-Seq]</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56288">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56288</ext-link><comment>NCBI The Gene Expression Omnibus, GSE56288 (GSM1358397)</comment></element-citation><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Asangani IA</collab><collab>Dommeti VL</collab><collab>Wang X</collab><collab>Malik R</collab><collab>Cieslik M</collab><collab>Yang R</collab><collab>Escara-Wilke J</collab><collab>Wilder-Romans K</collab><collab>Dhanireddy S</collab><collab>Engelke C</collab><collab>Iyer MK</collab><collab>Jing X</collab><collab>Wu YM</collab><collab>Cao X</collab><collab>Qin XS</collab><collab>Wang S</collab><collab>Feng FY</collab><collab>Chinnaiyan AM.</collab></person-group><year iso-8601-date="2014">2014</year><source>Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer [ChIP-Seq]</source><ext-link ext-link-type="uri" xlink:href="https://www-ncbi-nlm-nih-gov /geo/query/acc.cgi?acc=GSE55062">https://www-ncbi-nlm-nih-gov /geo/query/acc.cgi?acc=GSE55062</ext-link><comment>NCBI The Gene Expression Omnibus, GSE56288 (GSM1328950)</comment></element-citation><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Barfeld SJ</collab><collab>Urbanucci A</collab><collab>Fazli L</collab><collab>Rennie PS</collab><collab>Yegnasubramanian V</collab><collab>de Marzo AM</collab><collab>Thiede B</collab><collab>Harri IM</collab><collab>Hicks JL</collab><collab>Mills IG.</collab></person-group><year iso-8601-date="2017">2017</year><source>Overexpression of c-Myc antagonises transcriptional output of the androgen receptor in prostate cancer [ChIP-Seq]</source><ext-link ext-link-type="uri" xlink:href="https://www-ncbi-nlm-nih-gov /geo/query/acc.cgi?acc=GSE73994">https://www-ncbi-nlm-nih-gov /geo/query/acc.cgi?acc=GSE73994</ext-link><comment>NCBI The Gene Expression Omnibus, GSE73994 (GSM1907200)</comment></element-citation><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>ENCODE Project Consortium</collab></person-group><year iso-8601-date="2016">2016</year><source>SREBF1 ChIP-seq on human MCF-7</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE91561">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE91561</ext-link><comment>NCBI The Gene Expression Omnibus, GSE91561 (ENCFF911YFI)</comment></element-citation><element-citation id="dataset8" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>ENCODE Project Consortium</collab></person-group><year iso-8601-date="2011">2011</year><source>SREBF1 ChIP-seq on human HepG2 treated with insulin</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM935627">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM935627</ext-link><comment>NCBI The Gene Expression Omnibus, GSE31477 (GSM935627; ENCFF000XXR)</comment></element-citation><element-citation id="dataset9" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Latonen L</collab><collab>Afyounian E</collab><collab>JylhÃ¤ A</collab><collab>NÃ¤ttinen J</collab><collab>Aapola U</collab><collab>Annala M</collab><collab>Kivinummi KK</collab><collab>Tammela TTL</collab><collab>Beuerman RW</collab><collab>Uusitalo H</collab><collab>Nykter M</collab><collab>Visakorpi T.</collab></person-group><year iso-8601-date="2018">2018</year><source>Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression</source><ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41467-018-03573-6#Sec31">https://www.nature.com/articles/s41467-018-03573-6#Sec31</ext-link><comment>Peptide Atlas repository, PASS01126</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-62592-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>